Novel approaches to bone comorbidity in Cushing's disease: an update.
Bone mineral density
Cushing’s disease
Glucocorticoids
Osteoporosis
Vertebral fractures
Vertebral morphometry
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
accepted:
30
06
2022
pubmed:
19
7
2022
medline:
26
10
2022
entrez:
18
7
2022
Statut:
ppublish
Résumé
Skeletal complications are frequent and clinically relevant findings in Cushing's disease (CD) since an uncoupled suppressed bone formation and enhanced bone resorption leads to a marked skeletal damage with a rapid increase of fracture risk. Reduced Bone Mineral Density (BMD) has been consistently reported and osteopenia or osteoporosis are typical findings in patients with CD. Vertebral Fractures (VFs) are frequently reported and may occur even in patients with an only mild reduction of BMD, representing nowadays a still under- or misdiagnosed comorbidity of these patients being frequently asymptomatic. A novel approach combining different available tools such as BMD evaluation and vertebral morphometry, in order to improve diagnosis, management, and follow-up of bone comorbidity in all patients affected by CD, is needed. This approach is foreseen to be a crucial part of management of patients with CD, particularly in Pituitary Tumor Center of Excellence since VFs, the landmark of the bone involvement, may occur early in the history of the disease and may represent a relevant risk factor for further fractures, reduced quality of life and survival and need for pharmacologic prevention and treatment.
Identifiants
pubmed: 35849272
doi: 10.1007/s11102-022-01252-w
pii: 10.1007/s11102-022-01252-w
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
754-759Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Fleseriu M, Auchus R, Bancos I et al (2021) Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847–875. https://doi.org/10.1016/S2213-8587(21)00235-7
doi: 10.1016/S2213-8587(21)00235-7
pubmed: 34687601
Frara S, Melin Uygur M, di Filippo L et al (2022) High prevalence of vertebral fractures associated with preoperative GH levels in patients with recent diagnosis of acromegaly. J Clin Endocrinol Metab 107(7):e2843–e2850. https://doi.org/10.1210/clinem/dgac183
doi: 10.1210/clinem/dgac183
pubmed: 35349698
Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18(10):1319–1328. https://doi.org/10.1007/s00198-007-0394-0
doi: 10.1007/s00198-007-0394-0
pubmed: 17566815
Chotiyarnwong P, McCloskey EV (2020) Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment. Nat Rev Endocrinol 16(8):437–447. https://doi.org/10.1038/s41574-020-0341-0
doi: 10.1038/s41574-020-0341-0
pubmed: 32286516
Frara S, Allora A, di Filippo L et al (2021) Osteopathy in mild adrenal Cushing’s syndrome and Cushing disease. Best Pract Res Clin Endocrinol Metab 35(2):101515. https://doi.org/10.1016/j.beem.2021.101515
doi: 10.1016/j.beem.2021.101515
pubmed: 33795196
Manelli F, Giustina A (2000) Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab 11(3):79–85. https://doi.org/10.1016/s1043-2760(00)00234-4
doi: 10.1016/s1043-2760(00)00234-4
pubmed: 10707047
Mazziotti G, Giustina A (2013) Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 9(5):265–276. https://doi.org/10.1038/nrendo.2013.5
doi: 10.1038/nrendo.2013.5
pubmed: 23381030
Skversky AL, Kumar J, Abramowitz MK, Kaskel FJ, Melamed ML (2011) Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001–2006. J Clin Endocrinol Metab 96(12):3838–3845. https://doi.org/10.1210/jc.2011-1600
doi: 10.1210/jc.2011-1600
pubmed: 21956424
pmcid: 3232615
Mazziotti G, Formenti AM, Adler RA et al (2016) Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines. Endocrine 54(3):603–611. https://doi.org/10.1007/s12020-016-1146-8
doi: 10.1007/s12020-016-1146-8
pubmed: 27766553
Canalis E, Bilezikian JP, Angeli A, Giustina A (2004) Perspectives on glucocorticoid-induced osteoporosis. Bone 34(4):593–598. https://doi.org/10.1016/j.bone.2003.11.026
doi: 10.1016/j.bone.2003.11.026
pubmed: 15050888
Buckley L, Guyatt G, Fink HA et al (2017) (2017) American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis [published correction appears in Arthritis Rheumatol 2017 Nov; 69(11):2246]. Arthritis Rheumatol. 69(8):1521–1537. https://doi.org/10.1002/art.40137
doi: 10.1002/art.40137
pubmed: 28585373
Bonadonna S, Burattin A, Nuzzo M et al (2005) Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol 152(2):199–205. https://doi.org/10.1530/eje.1.01841
doi: 10.1530/eje.1.01841
pubmed: 15745926
Donini LM, Busetto L, Bischoff SC et al (2022) Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Clin Nutr 41(4):990–1000. https://doi.org/10.1016/j.clnu.2021.11.014
doi: 10.1016/j.clnu.2021.11.014
pubmed: 35227529
Chiodini I, Vainicher CE, Morelli V et al (2016) Mechanisms in endocrinology: endogenous subclinical hypercortisolism and bone: a clinical review. Eur J Endocrinol 175(6):R265–R282. https://doi.org/10.1530/EJE-16-0289
doi: 10.1530/EJE-16-0289
pubmed: 27412441
dos Santos CV, Vieira Neto L, Madeira M et al (2015) Bone density and microarchitecture in endogenous hypercortisolism. Clin Endocrinol (Oxf) 83(4):468–474. https://doi.org/10.1111/cen.12812
doi: 10.1111/cen.12812
Apaydın T, Yavuz DG (2021) Assessment of non-traumatic vertebral fractures in Cushing’s syndrome patients. J Endocrinol Invest 44(8):1767–1773. https://doi.org/10.1007/s40618-020-01496-y
doi: 10.1007/s40618-020-01496-y
pubmed: 33420960
Chiodini I, Carnevale V, Torlontano M et al (1998) Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing’s syndrome. J Clin Endocrinol Metab 83(6):1863–1867. https://doi.org/10.1210/jcem.83.6.4880
doi: 10.1210/jcem.83.6.4880
pubmed: 9626110
Mazziotti G, Bilezikian J, Canalis E, Cocchi D, Giustina A (2012) New understanding and treatments for osteoporosis. Endocrine 41(1):58–69. https://doi.org/10.1007/s12020-011-9570-2
doi: 10.1007/s12020-011-9570-2
pubmed: 22180055
Belaya ZE, Hans D, Rozhinskaya LY et al (2015) The risk factors for fractures and trabecular bone-score value in patients with endogenous Cushing’s syndrome. Arch Osteoporos 10:44. https://doi.org/10.1007/s11657-015-0244-1
doi: 10.1007/s11657-015-0244-1
pubmed: 26608406
Mazziotti G, Frara S, Giustina A (2018) Pituitary diseases and bone. Endocr Rev 39(4):440–488. https://doi.org/10.1210/er.2018-00005
doi: 10.1210/er.2018-00005
pubmed: 29684108
Formenti AM, Dalla Volta A, di Filippo L, Berruti A, Giustina A (2021) Effects of medical treatment of prostate cancer on bone health. Trends Endocrinol Metab 32(3):135–158. https://doi.org/10.1016/j.tem.2020.12.004
doi: 10.1016/j.tem.2020.12.004
pubmed: 33509658
di Filippo L, Formenti AM, Doga M, Pedone E, Rovere-Querini P, Giustina A (2021) Radiological thoracic vertebral fractures are highly prevalent in COVID-19 and predict disease outcomes. J Clin Endocrinol Metab 106(2):e602–e614. https://doi.org/10.1210/clinem/dgaa738
doi: 10.1210/clinem/dgaa738
pubmed: 33159451
Tauchmanovà L, Pivonello R, Di Somma C et al (2006) Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. J Clin Endocrinol Metab 91(5):1779–1784. https://doi.org/10.1210/jc.2005-0582
doi: 10.1210/jc.2005-0582
pubmed: 16522701
Chiodini I, Guglielmi G, Battista C et al (2004) Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effects of subclinical hypercortisolism and gonadal status. J Clin Endocrinol Metab 89(5):2237–2241. https://doi.org/10.1210/jc.2003-031413
doi: 10.1210/jc.2003-031413
pubmed: 15126547
Randazzo ME, Grossrubatscher E, Dalino Ciaramella P, Vanzulli A, Loli P (2012) Spontaneous recovery of bone mass after cure of endogenous hypercortisolism. Pituitary 15(2):193–201. https://doi.org/10.1007/s11102-011-0306-3
doi: 10.1007/s11102-011-0306-3
pubmed: 21476062
Vestergaard P, Lindholm J, Jørgensen JO et al (2002) Increased risk of osteoporotic fractures in patients with Cushing’s syndrome. Eur J Endocrinol 146(1):51–56. https://doi.org/10.1530/eje.0.1460051
doi: 10.1530/eje.0.1460051
pubmed: 11751067
Mancini T, Porcelli T, Giustina A (2010) Treatment of Cushing disease: overview and recent findings. Ther Clin Risk Manag. 6:505–516. https://doi.org/10.2147/TCRM.S12952
doi: 10.2147/TCRM.S12952
pubmed: 21063461
pmcid: 2963160
Chiloiro S, Giampietro A, Frara S et al (2020) Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. J Clin Endocrinol Metab. 105(3):dgz054. https://doi.org/10.1210/clinem/dgz054
doi: 10.1210/clinem/dgz054
pubmed: 31613969
Fleseriu M, Castinetti F, Gadelha M et al (2022) Osilodrostat for the treatment of Cushing’s disease: efficacy, stability, and persistence—authors’ reply. Lancet Diabetes Endocrinol 10(6):385–387. https://doi.org/10.1016/S2213-8587(22)00135-8
doi: 10.1016/S2213-8587(22)00135-8
pubmed: 35597255
Canalis E, Giustina A (2001) Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab 86(12):5681–5685. https://doi.org/10.1210/jcem.86.12.8066
doi: 10.1210/jcem.86.12.8066
pubmed: 11739419
Angeli A, Guglielmi G, Dovio A et al (2006) High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39(2):253–259. https://doi.org/10.1016/j.bone.2006.02.005
doi: 10.1016/j.bone.2006.02.005
pubmed: 16574519
Mazziotti G, Formenti AM, Frara S et al (2017) Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. Eur J Endocrinol 177(5):R231–R248. https://doi.org/10.1530/EJE-17-0154
doi: 10.1530/EJE-17-0154
pubmed: 28583942
Scillitani A, Mazziotti G, Di Somma C et al (2014) Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int 25(2):441–446. https://doi.org/10.1007/s00198-013-2588-y
doi: 10.1007/s00198-013-2588-y
pubmed: 24311114
Giustina A, Bouillon R, Binkley N et al (2020) Controversies in vitamin D: a statement from the third international conference. JBMR Plus. 4(12):e10417. https://doi.org/10.1002/jbm4.10417
doi: 10.1002/jbm4.10417
pubmed: 33354643
pmcid: 7745884
Bilezikian JP, Formenti AM, Adler RA et al (2021) Vitamin D: dosing, levels, form, and route of administration: does one approach fit all? Rev Endocr Metab Disord 22(4):1201–1218. https://doi.org/10.1007/s11154-021-09693-7
doi: 10.1007/s11154-021-09693-7
pubmed: 34940947
pmcid: 8696970
Pedersini R, Amoroso V, Maffezzoni F et al (2019) Association of fat body mass with vertebral fractures in postmenopausal women with early breast cancer undergoing adjuvant aromatase inhibitor therapy. JAMA Netw Open. 2(9):e1911080. https://doi.org/10.1001/jamanetworkopen.2019.11080
doi: 10.1001/jamanetworkopen.2019.11080
pubmed: 31560383
pmcid: 6777242
Hall GM, Daniels M, Doyle DV, Spector TD (1994) Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 37(10):1499–1505. https://doi.org/10.1002/art.1780371014
doi: 10.1002/art.1780371014
pubmed: 7945476
Mok CC, Ying KY, To CH et al (2011) Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann Rheum Dis 70(5):778–784. https://doi.org/10.1136/ard.2010.143453
doi: 10.1136/ard.2010.143453
pubmed: 21187295
Di Somma C, Colao A, Pivonello R et al (1998) Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing’s disease. Clin Endocrinol (Oxf) 48(5):655–662. https://doi.org/10.1046/j.1365-2265.1998.00486.x
doi: 10.1046/j.1365-2265.1998.00486.x
Mancini T, Doga M, Mazziotti G, Giustina A (2004) Cushing’s syndrome and bone. Pituitary 7(4):249–252. https://doi.org/10.1007/s11102-005-1051-2
doi: 10.1007/s11102-005-1051-2
pubmed: 16010458
Zilio M, Barbot M, Ceccato F et al (2014) Diagnosis and complications of Cushing’s disease: gender-related differences. Clin Endocrinol (Oxf) 80(3):403–410. https://doi.org/10.1111/cen.12299
doi: 10.1111/cen.12299
Kim SY, Davydov O, Hans D, Bockman R (2015) Insights on accelerated skeletal repair in Cushing’s disease. Bone Rep. 2:32–35. https://doi.org/10.1016/j.bonr.2015.03.001
doi: 10.1016/j.bonr.2015.03.001
pubmed: 28377951
pmcid: 5365170
Formenti AM, Maffezzoni F, Doga M, Mazziotti G, Giustina A (2017) Growth hormone deficiency in treated acromegaly and active Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab 31(1):79–90. https://doi.org/10.1016/j.beem.2017.03.002
doi: 10.1016/j.beem.2017.03.002
pubmed: 28477735
Giustina A, Bussi AR, Jacobello C, Wehrenberg WB (1995) Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 80(1):122–129. https://doi.org/10.1210/jcem.80.1.7829600
doi: 10.1210/jcem.80.1.7829600
pubmed: 7829600
Frara S, Rodriguez-Carnero G, Formenti AM, Martinez-Olmos MA, Giustina A, Casanueva FF (2020) Pituitary tumors centers of excellence. Endocrinol Metab Clin North Am 49(3):553–564. https://doi.org/10.1016/j.ecl.2020.05.010
doi: 10.1016/j.ecl.2020.05.010
pubmed: 32741488